Allergy Standards Ltd deepens footprint in the ‘Bay Area’ as Irish Minister for Health visits
15 mars 2019 18h31 HE
|
Allergy Standards Limited
SAN FRANCISCO, March 15, 2019 (GLOBE NEWSWIRE) -- Allergy Standards Limited (ASL) has been expanding its activities on the West Coast and a visit to San Francisco, Berkeley, and Los Angeles by its...
Allergy Standards’ Leadership Team Invited to Prestigious Scientific and Political High-Level Discussions
15 mars 2019 15h34 HE
|
Allergy Standards Limited
Boston, MA, March 15, 2019 (GLOBE NEWSWIRE) -- Allergy Standards Ltd (ASL), an international certification company which develops scientific testing protocols to reduce asthma and allergy triggers,...
Certification Program Attends the 2019 Science Foundation Ireland Award Ceremony in MIT
12 mars 2019 10h03 HE
|
Allergy Standards Limited
Boston, USA., March 12, 2019 (GLOBE NEWSWIRE) -- The leadership team of the asthma & allergy friendly® Certification Program, a joint venture between Allergy Standards Limited (ASL) and the...
Dr Joey DeCourcey invited Speaker at the 2019 Cleaning Products Conference Europe.
08 mars 2019 04h57 HE
|
Allergy Standards Limited
Dublin, Ireland, March 08, 2019 (GLOBE NEWSWIRE) -- Allergy Standards Limited (ASL) announced today that ASL’s Senior Scientific Officer, Dr Joey DeCourcey, will feature at the Cleaning Products...
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
26 févr. 2019 16h07 HE
|
Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...
Equillium to Present at Leerink Partners Global Healthcare Conference
21 févr. 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce...
Equillium to Host Business Update Call on February 26
19 févr. 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with...
Strados Labs Adds Health Leaders to Management Team
12 févr. 2019 00h00 HE
|
Strados Labs
PHILADELPHIA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Strados Labs, creator of the world’s first remote respiratory monitoring platform, announced today the addition of three new executives to its...
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
19 déc. 2018 08h06 HE
|
Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
15 nov. 2018 16h07 HE
|
Equillium, Inc.
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease ...